IP Library Granted Patent US 8,541,006
Granted Patent B2
US 8,541,006 · App. 12/671,398 · Granted Sep 24, 2013

Methods and devices for the detection of biofilm

Inventors: Jeffrey G. Leid (Flagstaff, AZ); Timothy L. Vail (Parks, AZ); Jennifer M. Kofonow (Philadelphia, PA); Mark E. Shirtliff (Ellicott City, MD); Rebecca A. Brady (Laurel, MD)
Assignees: University of Maryland, Baltimore; The Arizona Board of Regents, a body corporate acting for and on behalf of Northern Arizona University
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,541,006
App. No.
12/671,398
Granted
Sep 24, 2013
Kind
B2
Abstract

The present invention provides methods and kits for biofilm detection.

Claims (29)

1. A method for detecting a probability for the presence of a Staphylococcus biofilm comprising:

a) contacting a test sample with one or more detectably labeled proteins,

wherein the one or more detectably labeled proteins are capable of binding antibodies present in the test sample, wherein the binding produces labeled antibodies;

b) contacting the labeled antibodies to a substrate comprising one or more immobilized biofilm markers selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:13, SEQ ID NO: 43 and a polypeptide comprising one or more antigenic fragments thereof; and

c) detecting binding of the labeled antibodies to the one or more immobilized biofilm markers, wherein binding indicates a probability for the presence of the Staphylococcus biofilm in the test sample.

2. The method of claim 1 wherein the contacting the labeled antibodies to a substrate comprises allowing the labeled antibodies to migrate along the substrate prior to contacting the one or more immobilized biofilm markers.

3. The method of claim 1 wherein the biofllm comprises Staphylococcus aureus.

4. The method of claim 3 wherein the Staphylococcus aureus comprises methicillin-resistant Staphylococcus aureus.

5. A method for diagnosing a probability for the presence of a Staphylococcus biofilm related disease in a subject, comprising:

a) contacting a test sample from the subject with one or more detectably labeled proteins, wherein the one or more detectably labeled proteins are capable of binding antibodies present in the test sample, wherein the binding produces labeled antibodies;

b) contacting the labeled antibodies to a substrate comprising one or more immobilized biofilm markers selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:13, SEQ ID NO: 43 and a polypeptide comprising one or more antigenic fragments thereof; and

c) detecting binding of the labeled antibodies to the one or more immobilized biofilm markers, wherein binding indicates a probability for the presence of a Staphylococcus biofilm related disease in the subject.

6. The method of claim 5 , wherein the biofilm related disease is osteomyelitis.

7. Biofilm detection substrates for detecting a probability for the presence of a Staphylococcus biofilm comprising:

a) a test well comprising one or more detectably labeled proteins, wherein the one or more detectably labeled proteins are capable of binding to biofilm antibodies present in a test sample; and

b) one or more immobilized Staphylococcus biofilm markers capable of binding to labeled antibodies selected from the group consisting of SEQ ID NO: 1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:13, SEQ ID NO: 43 and a polypeptide comprising one or more antigenic fragments thereof.

8. A kit for detecting a probability for the presence of a Staphylococcus biofilm comprising the substrates of claim 7 , wherein the one or more detectably labeled proteins of a) are capable of binding to biofilm antibodies present in a test sample, wherein the test sample is a bodily fluid sample from a patient.

9. The method of claim 1 , wherein the one or more immobilized biofilm markers of b) is SEQ ID NO:1 or a polypeptide comprising one or more antigenic fragments thereof.

10. The method of claim 1 , wherein the one or more immobilized biofilm markers of b) is SEQ ID NO:2 or a polypeptide comprising one or more antigenic fragments thereof.

11. The method of claim 1 , wherein the one or more immobilized biofilm markers of b) is SEQ ID NO:3 or a polypeptide comprising one or more antigenic fragments thereof.

12. The method of claim 1 , wherein the one or more immobilized biofilm markers of b) is SEQ ID NO:13 or a polypeptide comprising one or more antigenic fragments thereof.

13. The method of claim 1 , wherein the one or more immobilized biofilm markers of b) is SEQ ID NO:43 or a polypeptide comprising one or more antigenic fragments thereof.

14. The method of claim 5 , wherein the one or more immobilized biofilm markers of b) is SEQ ID NO:1 or a polypeptide comprising one or more antigenic fragments thereof.

15. The method of claim 5 , wherein the one or more immobilized biofilm markers of b) is SEQ ID NO:2 or a polypeptide comprising one or more antigenic fragments thereof.

16. The method of claim 5 , wherein the one or more immobilized biofilm markers of b) is SEQ ID NO:3 or a polypeptide comprising one or more antigenic fragments thereof.

17. The method of claim 5 , wherein the one or more immobilized biofilm markers of b) is SEQ ID NO:13 or a polypeptide comprising one or more antigenic fragments thereof.

18. The method of claim 5 , wherein the one or more immobilized biofilm markers of b) is SEQ ID NO:43 or a polypeptide comprising one or more antigenic fragments thereof.

19. The biofilm detection substrates of claim 7 , wherein the one or more immobilized biofilm markers of b) is SEQ ID NO:1 or a polypeptide comprising one or more antigenic fragments thereof.

20. The biofilm detection substrates of claim 7 , wherein the one or more immobilized biofilm markers of b) is SEQ ID NO:2 or a polypeptide comprising one or more antigenic fragments thereof.

Assignments (5)
CONFIRMATORY LICENSE Recorded Jun 2, 2014
From: NORTHERN ARIZONA UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 033006/0760 →
CONFIRMATORY LICENSE Recorded Dec 13, 2013
From: NORTHERN ARIZONA UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 031815/0195 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 20, 2013
From: BRADY, REBECCA; SHIRTLIFF, MARK
To: UNIVERSITY OF MARYLAND, BALTIMORE
Reel/Frame 031046/0149 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 20, 2013
From: BRADY, REBECCA; SHIRTLIFF, MARK
To: UNIVERSITY OF MARYLAND, BALTIMORE
Reel/Frame 031046/0241 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 20, 2013
From: LEID, JEFFREY G.; VAIL, TIMOTHY L.; KOFONOW, JENNIFER M.
To: THE ARIZONA BOARD OF REGENTS, A BODY CORPORATE ACTING FOR AND ON BEHALF OF NORTHERN ARIZONA UNIVERSITY
Reel/Frame 031049/0429 →
Continuity (3)
Provisional Application 60952786 · Jul 30, 2007
Provisional Application 60974258 · Sep 21, 2007
Related Publication 20100285496A1 · Nov 11, 2010